Skip to main content

Table 2 Main decision-tree inputs

From: Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

 

Input

Reference

Invalid results and positivity rate of selected biomarkers

EGFR (% positive / % invalid)

13.6% / 1.70%

[15]

ALK (% positive / % invalid)

3.4% / 2.60%

[15]

ROS1 (% positive / % invalid)

1.0% / 3.30%

[15]

 PD-L1 (TPS ≥ 50%) (% positive / % invalid)

32.5% / 1.00%

Expert panel / [15]

Probability of re-biopsy

 Percentage of invalid results re-biopsied

33.3%

Expert panel

ROS1 determination strategies

 IHC

10.0%

Expert panel

 FISH

30.0%

Expert panel

 REFLEX to FISH

55.0%

Expert panel

 NGS

5.0%

Expert panel

  1. EGFR Epidermal growth factor receptor, ALK Anaplastic lymphoma kinase, ROS1 C-ros oncogene 1, PD-L1 Programmed death-ligand 1, IHC Immunohistochemistry, FISH Fluorescent in situ hybridization, NGS Next-generation sequencing